靶向m⁶A调控因子的肿瘤治疗策略研究进展：从机制到临床转化

[1] Liu S, Chen S, Tang C, et al. The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development[J]. Front Oncol, 2022, 12: 970833.

[2] Wen T, Li T, Xu Y, et al. The role of m6A epigenetic modifications in tumor coding and non-coding RNA processing[J]. Cell communication and signaling : CCS, 2023, 21(1): 355.

[3] Wang T, Kong S, Tao M, et al. The potential role of RNA N6-methyladenosine in Cancer progression[J]. Molecular cancer, 2020, 19(1): 88.

[4] Xu Z, Sun B, Wang W, et al. Research progress on m6A and drug resistance in gastrointestinal tumors[J]. Front Pharmacol, 2025, 16: 1565738.

[5] Pan J, Huang T, Deng Z, et al. Roles and therapeutic implications of m6A modification in cancer immunotherapy[J]. Frontiers in immunology, 2023, 14: 1132601.

[6] Liu Z H, Ma P, He Y, et al. The Mechanism and Latest Progress of m6A Methylation in the Progression of Pancreatic Cancer[J]. International journal of biological sciences, 2025, 21(3): 1187-1201.

[7] Liu W W, Zhang Z Y, Wang F, et al. Emerging roles of m6A RNA modification in cancer therapeutic resistance[J]. Experimental hematology & oncology, 2023, 12(1): 21.

[8] Liu Z X, Li L M, Sun H L, et al. Link Between m6A Modification and Cancers[J]. Frontiers in bioengineering and biotechnology, 2018, 6: 89.

[9] Yan Y, Yin J, Ding Q, et al. M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges[J]. Front Oncol, 2025, 15: 1622359.

[10] Guo J, Zheng J, Zhang H, et al. RNA m6A methylation regulators in ovarian cancer[J]. Cancer cell international, 2021, 21(1): 609.

[11] Shi T, Zhang H, Chen Y. The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes[J]. Cell Biosci, 2025, 15(1): 27.

[12] Meng Q, Schatten H, Zhou Q, et al. Crosstalk between m6A and coding/non-coding RNA in cancer and detection methods of m6A modification residues[J]. Aging, 2023, 15(13): 6577-6619.

[13] Kapadia B, Roychowdhury A, Kayastha F, et al. m6A eraser ALKBH5/treRNA1/DDX46 axis regulates BCR expression[J]. Neoplasia (New York, NY), 2025, 62: 101144.

[14] Mao Z, Wang B, Zhang T, et al. The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications[J]. Cell Death Dis, 2023, 14(11): 734.

[15] Jayasree PJ, Dutta S, Karemore P, et al. Crosstalk Between m6A RNA Methylation and miRNA Biogenesis in Cancer: An Unholy Nexus[J]. Molecular biotechnology, 2024, 66(11): 3042-3058.

[16] Gao R, Ye M, Liu B, et al. m6A Modification: A Double-Edged Sword in Tumor Development[J]. Front Oncol, 2021, 11: 679367.

[17] Xu X, Zhao J, Yang M, et al. The emerging roles of N6-methyladenosine RNA modifications in thyroid cancer[J]. European journal of medical research, 2023, 28(1): 475.

[18] Wang L, Tang Y. N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications[J]. Biomed Pharmacother, 2023, 163: 114846.

[19] Li X, Peng L, Yang X, et al. N6-methyladenosine RNA methylation, a new hallmark of metabolic reprogramming in the immune microenvironment[J]. Frontiers in immunology, 2024, 15: 1464042.

[20] Liu Z, Zhong J, Zeng J, et al. Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy[J]. Frontiers in immunology, 2021, 12: 735170.

[21] Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature, 2021, 593(7860): 597-601.

[22] Xiao H, Zhao R, Meng W, et al. Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer[J]. Journal of pharmaceutical analysis, 2023, 13(6): 625-639.

[23] Liu J, Harada B T, He C. Regulation of gene expression by N6-methyladenosine in cancer[J]. Trends in cell biology, 2019, 29(6): 487-499.

[24] Meng H, Jalal M, Wang H, et al. 17-AAG promotes the degradation of HSP90 client METTL3 to suppress MYC RNA m(6)A modification and expression in colorectal cancer[J]. International journal of biological macromolecules, 2026, 337(Pt 1): 149421.

[25] Huang Y, Su R, Sheng Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia[J]. Cancer cell, 2019, 35(4): 677-691.

[26] Su R, Dong L, Li Y, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion[J]. Cancer cell, 2020, 38(1): 79-96.

[27] He Z, Wang D, Zhao W, et al. ALKBH5-Mediated ITGB1 m6A Modification in Ovarian Cancer Progression and Immune Evasion[J]. NPJ precision oncology, 2025, 9(1): 399.

[28] Malacrida A, Di Domizio A, Bentivegna A, et al. MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines[J]. Biology (Basel), 2022, 11(1): 70.

[29] Chen A, Zhang V X, Zhang Q, et al. Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma[J]. Gut, 2024, 74(1): 90-102.

[30] Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability[J]. Nature, 2014, 505(7481): 117-120.

[31] Huang H, Weng H, Sun W, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation[J]. Nature cell biology, 2018, 20(3): 285-295.

[32] Müller S, Bley N, Busch B, et al. The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer[J]. Nucleic acids research, 2020, 48(15): 8576-8590.

[33] Wallis N, Gershon T, Shaaby S, et al. AVJ16 inhibits lung carcinoma by targeting IGF2BP1[J]. Oncogene, 2025, 44(35): 3239-3254.

[34] Singh A, Singh V, Wallis N, et al. Development of a specific and potent IGF2BP1 inhibitor: A promising therapeutic agent for IGF2BP1-expressing cancers[J]. European journal of medicinal chemistry, 2024, 263: 115940.

[35] Paris J, Morgan M, Campos J, et al. Targeting the RNA m(6)A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia[J]. Cell stem cell, 2019, 25(1): 137-148.

[36] Han D, Liu J, Chen C, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells[J]. Nature, 2019, 566(7743): 270-274.

[37] Xiao S, Ma S, Sun B, et al. The tumor-intrinsic role of the m(6)A reader YTHDF2 in regulating immune evasion[J]. Science immunology, 2024, 9(95): eadl2171.

[38] Mao M, Zhang J J, Xu Y P, et al. Regulatory effects of natural products on N6-methyladenosine modification: A novel therapeutic strategy for cancer[J]. Drug discovery today, 2024, 29(2): 103875.

[39] Deng LJ, Deng WQ, Fan SR, et al. m6A modification: recent advances, anticancer targeted drug discovery and beyond[J]. Molecular cancer, 2022, 21(1): 52.

[40] Liu X, Ma C, Liu H, et al. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer[J]. Journal of cancer research and clinical oncology, 2022, 148(10): 2803-2814.

[41] Liao Y, Han P, Zhang Y, et al. Physio-pathological effects of m6A modification and its potential contribution to melanoma[J]. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021,23(11):2269-2279.

[42] Qu Y, Gao N, Zhang S, et al. Role of N6-methyladenosine RNA modification in cancer[J]. MedComm, 2024,5(9):e715.

[43] Lin Y, Li J, Liang S, et al. Pan-cancer Analysis Reveals m6A Variation and Cell-specific Regulatory Network in Different Cancer Types[J]. Genomics, proteomics & bioinformatics, 2024,22(4):133-146.

[44] Sivalingam A M, Sureshkumar D D. The Central Role of m6A as Epigenetic Regulator in Metabolic Disorders of Therapeutic Potential and Clinical Implications[J]. Molecular neurobiology, 2025, 63(1): 247.

[45] Liu S, Liu M, Li Y, et al. N6-methyladenosine-dependent signaling in colorectal cancer: Functions and clinical potential[J]. Critical reviews in oncology/hematology, 2024, 198: 104360.

[46] Gu J, Cao H, Chen X, et al. RNA m6A modifications regulate crosstalk between tumor metabolismand immunity[J]. Wiley interdisciplinary reviews RNA, 2024, 15(1): e1829.

[47] Zhang Z, Liu F, Chen W, et al. The importance of N6-methyladenosine modification in tumor immunity and immunotherapy[J]. Experimental hematology & oncology, 2022, 11(1): 30.

[48] Yang M, Zhou Y, Yang L, et al. M6AREG 2.0: the landscape of m6A-centered crosstalk with diverse epigenetic regulation[J]. Nucleic Acids Res, 2026, 54(D1): D1457-d1468.

[49] Rath S, Chakraborty D, Pradhan J, et al. Epigenomic interplay in tumor heterogeneity: Potential of epidrugs as adjunct therapy[J]. Cytokine, 2022, 157: 155967.

[50] Wang Y, Peng L, Wang F. M6A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma[J]. Cancer biology & therapy, 2024, 25(1): 2333590.

[51] Ji FH, Yang Z, Sun C, et al. Characterization of m6A methylation modifications and tumor microenvironment infiltration in thyroid cancer[J]. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023, 25(1): 269-282.

[52] Guo Y, Bai Y, Wang L, et al. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer[J]. Medicine, 2022, 101(26): e29818.